Deerfield Management Company, L.P. (Series C) Revolution Medicines, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,912,692 shares of RVMD stock, worth $161 Million. This represents 2.45% of its overall portfolio holdings.
Number of Shares
2,912,692
Previous 3,090,073
5.74%
Holding current value
$161 Million
Previous $120 Million
10.05%
% of portfolio
2.45%
Previous 2.52%
Shares
11 transactions
Others Institutions Holding RVMD
# of Institutions
266Shares Held
161MCall Options Held
260KPut Options Held
620K-
Vanguard Group Inc Valley Forge, PA14.9MShares$822 Million0.01% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$739 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA11.4MShares$629 Million0.09% of portfolio
-
Farallon Capital Management LLC San Francisco, CA11.3MShares$624 Million2.58% of portfolio
-
Baker Bros. Advisors LP New York, NY7.57MShares$417 Million3.67% of portfolio
About Revolution Medicines, Inc.
- Ticker RVMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,697,600
- Market Cap $4.83B
- Description
- Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...